Pharma Deals Review, Vol 2005, No 64 (2005)

Font Size:  Small  Medium  Large

Inyx Increases Capabilities in the Inhaled Drug Market

Business Review Editor

Abstract


Inyx has bought Celltech Manufacturing Services from UCB Group for a reported €27.5 M. This move will see UCB concentrate on Celltech’s R&D and commercial capabilities after acquiring the entire Celltech Group.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.